03 May

Unity Biotech IPO Raises $85M to Test Drugs for Diseases of Aging

Unity Biotechnology has yet to demonstrate that its drugs can treat diseases of aging in humans but it now has $85 million to start tests.

The Brisbane, CA, drug developer priced its initial public offering of 5 million shares late Wednesday at $17 apiece. That price was the midpoint of the $16 to $18 range it had previously set. Shares are expected to begin trading Thursday on the Nasdaq exchange under the stock symbol “UBX.”

Unity aims to treat diseases of aging at the cellular level. The company is developing drugs that target senescent cells– dormant cells that still secrete… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

02 May

Refuge Bio Turns to China for $25M Financing of Precision CRISPR R&D

DNA Double Helix

Refuge Biotechnologies, a company researching ways to use CRISPR gene editing to make cancer treatment more precise, has raised $25 million in financing to continue work on its preclinical drug pipeline.

China-based 3SBio and Sequoia China led the Series B round of investment in the Menlo Park, CA, company.

CRISPR-Cas9 technology uses modified versions of the Cas9 enzyme to bind to DNA and cut it, turning off the gene. Refuge says it has developed a way to modify the enzyme so it no longer cuts DNA. This “dead Cas9” still targets areas of the genome but it only activates when it… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

02 May

3rd Innovation Sessions – Healthcare Systems and Future Therapies – 4 June 2018, Brussels, Belgium

[Source: Research & Innovation] With the participation of the Commissioner for Research, Science and Innovation, Carlos Moedas, the Portuguese Trade & Investment Agency (AICEP), in cooperation with the Confederation of Portuguese Business (CIP), the Portuguese Agency for Innovation (ANI), the European Economic and Social Committee (EESC) and Eupportunity, would like to invite you to participate in the third “Innovation Sessions” event, a space to present and debate perspectives on innovative sectors.
The 2018 edition of the Innovation Sessions will focus on Healthcare Systems and Future Therapies. The Innovation Sessions bring together key actors from the European Institutions and main stakeholders from both public and private sector, in an interactive format in view of stimulating the debate and developing partnerships.
The event will take place at the European Economic and Social Committee, in Brussels, from 12h30 to 18h00, including a networking cocktail.
Registration required until 15 May 2018

02 May

BIO’s 2018 Renewable Chemical Report Now Available

In a piece for Biofuels Digest, BIO’s Executive Vice President, Industrial & Environmental Section, Brent Erickson (@BErickson_BIO) shares BIO’s 2018 “Renewable Chemical Platforms Building the Biobased Economy” report, which documents the contribution that over 100 companies are making to grow the biobased economy.

BIO estimates the global economic value of the biobased economy to be $355.28 billion, with the United States generating 58 percent of that value – or $205 billion.

The 2018 report is your guide to understanding the landscape of the biobased economy, from small startups to large brand manufacturers, and the perfect resource for partnering with the hundreds of industrial biotech companies that will be at the 2018 World Congress on Industrial Biotechnology in Philadelphia, July 16-19.

Read the full piece below and sign up to receive your copy of the 2018 “Renewable Chemical Platforms Building the Biobased Economy” today. Also, remember to register for the World Congress and sign up for the Partnering Webinar on Tuesday, May 15, to learn about how to use BIO’s One-on-One Partnering, so you can hit the ground running and start partnering with industry at the world’s largest conference on industrial biotechnology.

The biobased economy encompasses the entire value chain of sustainable manufacturing – from the supply of renewable or waste feedstock, through biotech platforms, to production and use of biobased fuels and products. BIO is a global leader in advocating policies that support commercialization of emerging renewable chemical technologies and companies. We recently published our new 2018 report, “Renewable Chemical Platforms Building the Biobased Economy,” to document the contribution that over 100 companies are making to the growth of the biobased economy value chain.

The latest edition of BIO’s industry directory illustrates the rapid expansion of renewable chemical platforms and applications around the world. “Renewable Chemical Platforms Building the Biobased Economy” profiles companies located in 16 countries – from small startups to large brand manufacturers – that are commercializing renewable chemical applications. The new, one-of-a-kind publication highlights the location and commercial stage of these renewable chemical makers, succinctly describing each company’s technology, products, potential markets, partnerships, and funding. We invite everyone interested in the industry to click here to download a free copy.

In capturing a snapshot of the industry’s status today, the directory also provides a glimpse of the potential for the future. Renewable chemical technologies are expanding from the biobased plastics and biofuels currently on the market to the development of nutritional food additives, cosmetic and personal care ingredients, and new materials and fabrics. A promising area for the future is biological pest control and crop growth stimulants, which will bring the biobased economy full circle by improving the renewability of feedstocks. The biobased economy continues to generate new ideas and products.

The rapid evolution of the biobased economy poses a difficult task in estimating its size and contribution to overall domestic production. BIO estimates that on a global scale, the value of biofuels, renewable chemicals and polymers, enzymes, biobased materials and the agricultural inputs are worth $355.28 billion. Our estimate is drawn from industry studies and analyses that supplement official government statistics with industry surveys. Official government statistics by themselves rarely separate renewable chemical manufacturing from the petroleum industry. BIO’s new industry directory shows how some traditional chemical manufacturers are partnering with technology companies on renewable chemical projects.

The growth of renewable chemicals is strongest in certain manufacturing sectors. TEConomy Partners – a research, analysis and strategy consultancy based in Ohio – estimates that renewable chemicals generate 16 percent of the economic activity in some important sectors of the U.S. organic chemical manufacturing industry. The company also estimates that biobased materials contribute 24 percent of the economic value of the acetate fiber market. Those percentages are more substantial than many existing industry studies calculate.

“Renewable Chemical Platforms Building the Biobased Economy” offers a view of where biobased innovation in the chemical sector is taking place. The partnerships that are building the biobased economy are key. Most – if not all – of the companies in the new directory have attended, presented or engaged in partnering meetings at the annual BIO World Congress on Industrial Biotechnology. The annual conference is a great opportunity to explore opportunities in the rapidly growing biobased economy. This year, it returns to Philadelphia at the Pennsylvania Convention Center July 16 – 19.

BIO will continue to champion policies that help renewable chemical companies build the biobased economy. We will also continue to provide the industry the best opportunities for partnering and business development through our annual conferences. We hope our new directory, “Renewable Chemical Platforms Building the Biobased Economy,” will provide companies and their business partners a new tool to use and share and to further those important efforts.

02 May

Global Bilirubin Market Analysis 2018 Wuhan Yuancheng Gongchuang Technology, Chongqing …

Some of the leading manufacturers in the Bilirubin market included in the report are Maanshan Hui Zhi Biotech, Pingdingshanshi Huishengyuan Shengwuzhipin, Wuhan Yuancheng Gongchuang Technology, Chongqing Jingkang Biotechnology, Chengdu Tianyuan Natural Product, Chongqing Jiangxia …

01 May

FluGen May Seek Funding from $12M Gates-Backed Flu Vaccine Challenge

Last week, the Bill and Melinda Gates Foundation announced that it plans to provide researchers with up to $12 million in funding as part of a new initiative to support the development of a universal influenza vaccine.

The dollar amount isn’t huge: The National Institute of Allergy and Infectious Diseases reportedly spent about $64 million on universal flu vaccine research in the most recent fiscal year.

However, the Gates Foundation’s commitment to improving on the status quo in flu vaccines underscores the threat a major flu outbreak would pose to public health, says Paul Radspinner. He’s the co-founder and CEO… Read more »

UNDERWRITERS AND PARTNERS

          

          

            

01 May

A Bullish Play on Neurocrine Biosciences

Click to view a price quote on NBIX.

Click to research the Drugs industry.

01 May

How GMO Answers Marked Earth Month

Sustainability is a major food trend this year – it continues to enter our conversations, whether we’re talking about reducing food waste and plastic use or producing food in more earth conscious ways. People are asking more questions than ever before about the origins of food and its impact – not only on themselves but also on the world around them.

Yet, the environmental benefits of GMOs and how they check many boxes for sustainability has largely been missing from these conversations. Contrary to misconceptions, GMOs DO help protect the environment in more ways than most think.

To help spread the word about the environmental benefits of GMOs and encourage people to #RethinkEarthConscious foods, GMO Answers compiled a few big (well, billboard size) shareable suggestions based on common environmental questions asked on the GMO Answers website in a post called, Should GMOs Make You Rethink ‘Earth Conscious’ Foods? Yes.

  1. How are GMOs impacting the environment?
  2. What’s the deal with food waste and needing GMOs to help feed the world?
  3. Do GMOs contaminate the soil?
  4. What is the most beneficial impact of GMOs?

Put simply, GMOs have given farmers the ability to do more with less. They are also helping us solve major food challenges like citrus-greening disease, which is threatening an estimated 80% Florida’s citrus groves, and banana wilt virus in East Africa. Solving these issues on the farms where they start means local farmers can continue to make a living and provide enough orange juice and bananas to fill breakfast tables across the world.

So, the next time you’re engaging in conversations about sustainable foods – remember that GMOs are one tool in the modern farmer’s tool box that can benefit us all and the environment in many ways. Check out the GMO Answers website to read the entire post about GMOs, the environment, sustainability, and Earth Day!

01 May

Biotechnology industry in Taipei will give annual output of USD 1.69 bn

Taipei City Government announced that they had launched a biotechnology industry cluster as a build-operate-transfer (BOT) project in the City’s Nangang District. The Biotechnology industry is estimated to generate an annual economic output of more than USD 1.69 billion as estimated by the Taipei …

01 May

Bristol-Myers Latest to Drop IDO Studies in Wake of Incyte Failure

Drug giant Bristol-Myers Squibb is the latest to feel the shockwave caused by the failure of a widely watched cancer immunotherapy nearly a month ago.

Xconomy has learned that Bristol (NYSE: BMY) is curtailing work on three late-stage studies testing an experimental cancer drug that it bought for $800 million three years ago.

The agent was an IDO inhibitor, part of a drug class considered a top contender to expand the limited reach of cancer immunotherapy. Earlier this month, epacadostat, an IDO inhibitor from Delaware biotech Incyte (NASDAQ: INCY), failed in combination with the FDA-approved pembrolizumab (Keytruda) in Read more »

UNDERWRITERS AND PARTNERS